Evaluating Sacubitril/Valsartan Dose Dependence on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction.

Kazuhiko KidoChristopher BiancoMarco CaccamoWei FangGeorge Sokos

Published in: The Annals of pharmacotherapy (2020)

Sacubitril/valsartan 97/103- or 49/51-mg dose is associated with a lower mortality or hospitalization rate for HF in patients receiving sacubitril/valsartan compared with the 24/26-mg dose group.

Keyphrases

ejection fraction
cardiovascular events
heart failure
risk factors
type diabetes
atrial fibrillation